Tumor necrosis factor-alpha -308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients

Chinese Journal of Cancer

Volumn 31, Issue 1, 2012, Pages 29-35

  Talaat, Roba M ^a   Esmail, Ahmed A ^b   Elwakil, Reda ^c   Gurgis, Adel A ^a   Nasr, Mahmoud I ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Hepatitis C virus; Liver neoplasm; Polymorphism; Tumor necrosis factor

Indexed keywords

ADENINE; GUANINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; EGYPTIAN; ETHNIC GROUP; FEMALE; GENE; GENE FREQUENCY; GENE LOCATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION GENETICS; POPULATION RESEARCH; PROMOTER REGION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR NECROSIS FACTOR ALPHA 308 GENE; TUMOR NECROSIS FACTOR ALPHA BLOOD LEVEL;

ADULT; AGED; ALLELES; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856173209     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10258     Document Type: Article

References (50)

1. Shepard C, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis, 2005,5(9):558-567.
2. Dai C, Chuang W, Chang W, et al. Tumor necrosis factor alpha promoter polymorphism at position-308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis, 2006,193(1):98-101.
3. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med, 2001,345(1):41-52.
4. Donato F, Gelatti U, Limina R, et al. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene, 2006,25(27):3756-3770.
5. Egyptian Ministry of Health Annual report. 2007. Available at http://www.mohp.gov.eg/Main.asp.
6. Shobokshi O, Serebour F, Skakni L, et al. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol, 1999,58 (1):44-48.
7. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol, 2004,85(Pt 11):3173-3188.
8. Nafeh M, Abdel-Hamid M, Strickland G, et al. Hepatitis C in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg, 2002,66(5):633-638.
9. Abdel Hamid M, El Daly M, Molnegren V, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol, 2007,88 (5):1526-1531.
10. Koziel M. Cytokines in viral hepatitis. Semin Liver Dis, 1999, 19 (2):157-169.
11. Fan XG, Liu WE, Li CZ, et al. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediators Inflamm, 1998,7(4):295-297.
12. Wilson A, Symons J, McDowell T, et al. Effects of a polymorphismin the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA, 1997,94(7):3195-3199.
13. Ben-Ari Z, Mor E, Papo O, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol, 2003,98(1):144-150.
14. Fernandez-Mestre M, Gendzekhadze K, Rivas-Vetencourt P, et al. TNF-alpha-308 A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens, 2004,64(4):469-472.
15. Bendicho M, Guedes J, Silva N, et al. Polymorphism of cytokine genes (TGF-beta1, IFN-gamma, IL-6, IL-10, and TNFalpha) in patients with chronic pancreatitis. Pancreas, 2005,30(4):333-336.
16. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol, 1999,26(Suppl 57):16-21.
17. Koziel M, Dudley D, Afdhal N, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus-identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest, 1995,96 (5):2311-2321.
18. Odeh M, Sabo E, Srugo I, et al. Relationship between tumor necrosis factor-a and ammonia in patients with hepatic encephalopathy due to chronic liver failure. Ann Med, 2005,37 (8):603-612.
19. Falasca K, Ucciferri C, Dalessandro M, et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci, 2006,36(2):144-150.
20. Cua I, Hui J, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology, 2007,46(1):66-73.
21. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, et al. Induction of tumor necrosis factor a production by human hepatocytes in chronic viral hepatitis. J Exp Med, 1994,179(3): 841-848.
22. Chuang E, Del Vecchio A, Smolinski S, et al. Biomedicines to reduce inflammation but not viral load in chronic HCV: what's the sense? Trends Biotechnol, 2004,22(10):517-523.
23. Akpolat N, Yahsi S, Godekmerdan A, et al. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol, 2005,11 (21):3260-3263.
24. Kamal S, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology, 2006,43(4):771-779.
25. Thimme R, Wieland S, Steiger C, et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 2003,77(1):68-76.
26. Cha C, DeMatteo R. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol, 2005,19(1):25-37.
27. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene, 2006,25(27):3834-3847.
28. Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes lmmun, 1999,1(1):3-19.
29. Negoro K, Kinouchi Y, Hiwatashi N, et al. Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene. Gastroenterology, 1999,117(5):1062-1068.
30. Wilson A, di Giovine F, Blakemore A, et al. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Gene, 1992,1(5):353.
31. Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun, 2001,2(2):61-70.
32. Yee L, Tang J, Herrera J, et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes lmmun, 2000,1(6):386-390.
33. Tambur A, Ortegel J, Ben-Ari Z, et al. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation, 2001,71(10): 1475-1480.
34. Vidigal P, Germer J, Zein N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol, 2002,36(2):271-277.
35. Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumor necrosis factor-alpha, transforming growth factor beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol, 2003,71(2): 212-218.
36. Abbas Z, Moatter T, Hussainy A, et al. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol, 2005,11(42):6656-6661.
37. Ryder S. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut, 2003,52 Suppl 3:iii1-8.
38. Bruix J, Sherman M. Management of hepatocellular carcinoma: Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology, 2005,42(5):1208-1236.
39. Hajeer A, Hutchinson I. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech, 2000,50 (3): 216-228.
40. Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res, 2001, 52(2):113-116.
41. Powell E, Edwards-Smith C, Hay J, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 2000,31(4):828-833.
42. Zein N, Germer J, El-Zayadi A, et al. Ethnic differences in polymorphisms of tumor necrosis factor-a, interleukin-10, and transforming growth factor-β1 genes in patients with chronic hepatitis C virus infection. Am J Trop Med Hyg, 2004,70(4): 434-437
43. Ho S, Wang Y, Chen H, et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the-308 tumor necrosis factor-promoter gene. Cancer Causes Control, 2004,15(7):657-663.
44. Constantini P, Wawrzynowicz-Syczewska R, Clare M, et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-in terferon therapy. Liver, 2002,22(5):404-412.
45. Hohler T, Kruger A, Gerken G, et al. Tumor necrosis factor alpha promoter polymorphism at position-238 is associated with chronic active hepatitis C infection. J Med Virol, 1998,54 (3):173-177.
46. Brinkman B, Zuijdgeest D, Kaijzel E, et al. Relevance of the tumor necrosis factor alpha (TNFα)-308 promoter polymorphism in TNF-α gene regulation. J Inflamm, 1996,46(1):32-41.
47. Romero-Gomez M, Montes-Cano M, Otero-Fernandez M, et al. SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. Gut, 2004,53(3):446-450.
48. Louis E, Franchimont D, Piron A, et al. Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol, 1998,113(3):401-406.
49. Huizinga T, Westendorp R, Bollen E, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol, 1997,72(2):149-153
50. Talaat R. Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. Viral Immunol, 2010,23(2):151-157.